Evidence map›Paper›PMID 41886033›Full record

ArticleAnnals of surgical oncology2026

Prognostic Value of Combined Carbohydrate Antigen 19-9 and Duke Pancreatic Monoclonal Antigen Type 2 Assessment in Biliary Tract Cancer.

Ryuta Shintakuya, Kenichiro Uemura, Tatsuaki Sumiyoshi, Kenjiro Okada, Takumi Harada, Sho Tazuma, Yasutaka Ishii, Shiro Oka, Yoshiaki Murakami, Shinya Takahashi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ryuta ShintakuyaDepartment of Surgery, Graduate School of Biomedical and Health Science, Hiroshima University, Hiroshima, Japan.
Kenichiro UemuraDepartment of Surgery, Graduate School of Biomedical and Health Science, Hiroshima University, Hiroshima, Japan. umk@hiroshima-u.ac.jp.ORCID http://orcid.org/0000-0003-0003-6268
Tatsuaki SumiyoshiDepartment of Surgery, Graduate School of Biomedical and Health Science, Hiroshima University, Hiroshima, Japan.
Kenjiro OkadaDepartment of Surgery, Graduate School of Biomedical and Health Science, Hiroshima University, Hiroshima, Japan.
Takumi HaradaDepartment of Surgery, Graduate School of Biomedical and Health Science, Hiroshima University, Hiroshima, Japan.
Sho TazumaDepartment of Surgery, Graduate School of Biomedical and Health Science, Hiroshima University, Hiroshima, Japan.
Yasutaka IshiiDepartment of Gastroenterology and Metabolism, Graduate School of Biomedical and Health Science, Hiroshima University, Hiroshima, Japan.
Shiro OkaDepartment of Gastroenterology and Metabolism, Graduate School of Biomedical and Health Science, Hiroshima University, Hiroshima, Japan.
Yoshiaki MurakamiDigestive Disease Center, Hiroshima Memorial Hospital, Hiroshima, Japan.
Shinya TakahashiDepartment of Surgery, Graduate School of Biomedical and Health Science, Hiroshima University, Hiroshima, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCarbohydrate antigen 19-9 (CA19-9) represents an established prognostic biomarker for biliary tract cancers (BTCs). Clinical utility remains limited among patients with Lewis antigen negativity or incomplete fucosyltransferase 3 (FUT3) gene function, conditions associated with absent or reduced CA19-9 production. Duke pancreatic monoclonal antigen type 2 (DUPAN-2), a biosynthetic precursor of CA19-9, shows compensatory elevation under such conditions. This study evaluated the prognostic significance of the combined preoperative assessment of CA19-9 and DUPAN-2 among patients with resectable BTCs. PATIENTS AND

methodsPatients who underwent curative-intent surgery for BTCs between 2009 and 2022 were included. Eligible patients were classified into four groups according to preoperative biomarker levels: normal CA19-9/normal DUPAN-2 (N/N), normal CA19-9/high DUPAN-2 (N/H), high CA19-9/normal DUPAN-2 (H/N), and high CA19-9/high DUPAN-2 (H/H). Clinicopathological features, overall survival (OS), and recurrence-free survival (RFS) were compared. Multivariate analyses identified independent prognostic factors.

resultsThe cohort included 276 patients with BTCs who underwent curative resection, comprising 41 intrahepatic cholangiocarcinomas, 72 hilar cholangiocarcinomas, 57 distal cholangiocarcinomas, 53 gallbladder carcinomas, and 53 ampullary carcinomas. Age and tumor distribution showed no significant intergroup differences. The N/N group demonstrated significantly superior OS and RFS (P < 0.001). Multivariate analysis identified the N/N profile as an independent favorable prognostic factor for OS and RFS (P < 0.001).

conclusionsConcurrent normal CA19-9 and DUPAN-2 levels independently predicted favorable outcomes. Combined preoperative biomarker assessment may contribute to prognostic stratification of BTCs, including among patients with Lewis antigen negativity or impaired FUT3 function.

Indexed as

Antigens, NeoplasmBiliary Tract NeoplasmsBiomarkers, TumorCA-19-9 AntigenAdultAgedAged, 80 and overFemaleFollow-Up StudiesHumansMaleMiddle AgedNeoplasm StagingPrognosisSurvival RateAntigens, NeoplasmBiomarkers, TumorCA-19-9 AntigenBiliary tract cancerCarbohydrate antigen 19-9Duke pancreatic monoclonal antigen type 2

Identifiers

PMID41886033
PMCPMC13242383

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.